{"nctId":"NCT02760368","briefTitle":"Evaluation of the Effectiveness and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease","startDateStruct":{"date":"2016-05-19","type":"ACTUAL"},"conditions":["Rheumatoid Arthritis"],"count":428,"armGroups":[{"label":"Arm 1: Olokizumab q4w","type":"EXPERIMENTAL","interventionNames":["Drug: Olokizumab","Drug: Placebo"]},{"label":"Arm 2: Olokizumab q2w","type":"EXPERIMENTAL","interventionNames":["Drug: Olokizumab"]},{"label":"Arm 3: Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Olokizumab","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\nSubjects may be enrolled in the study only if they meet all of the following criteria:\n\n* Subjects willing and able to sign informed consent\n* Subjects must have a diagnosis of adult onset RA classified by ACR/EULAR 2010 revised classification criteria for RA for at least 12 weeks prior to Screening.\n* Inadequate response to treatment with MTX for at least 12 weeks prior to Screening at a dose of 15 to 25 mg/week (or ≥10 mg/week if intolerant to higher doses).\n\n  * The dose and means of administering MTX must have been stable for at least 6 weeks prior to Screening.\n* Subjects must be willing to take folic acid or equivalent throughout the study\n* Subjects must have moderately to severely active RA disease as defined by all of the following:\n\n  * ≥6 tender joints (68 joint count) at Screening and baseline; and\n  * ≥6 swollen joints (66 joint count) at Screening and baseline; and\n  * CRP above ULN at Screening based on the central laboratory results.\n\nExclusion Criteria:\n\n* Diagnosis of any other inflammatory arthritis or systemic rheumatic disease (e.g., gout, psoriatic or reactive arthritis, Crohn's disease, Lyme disease, juvenile idiopathic arthritis, or systemic lupus erythematosus). However, subjects could have secondary Sjogren's syndrome or hypothyroidism\n* Subjects who were Steinbrocker class IV functional capacity (incapacitated, largely or wholly bed-ridden or confined to a wheelchair, with little or no self-care)\n* Prior exposure to any licensed or investigational compound directly or indirectly targeting IL-6 or IL-6R (including tofacitinib or other Janus kinases and spleen tyrosine kinase \\[SYK\\] inhibitors)\n* Prior treatment with cell-depleting therapies, including anti-CD20 or investigational agents (e.g., CAMPATH, anti-CD4, anti-CD5, anti-CD3, and anti-CD19)\n* Prior use of bDMARDs, with the following exception:\n\n  • Subjects who discontinued TNFi therapy due to a reason other than lack of efficacy were allowed to enter the study (TNFi therapy was not to be discontinued to facilitate a subject's participation in the study but should instead have been previously discontinued as part of a subject's medical management of RA). The use of TNFi therapy within the following windows prior to baseline was exclusionary:\n  1. 4 weeks for etanercept\n  2. 8 weeks for infliximab\n  3. 10 weeks for adalimumab, certolizumab, and golimumab\n* Use of parenteral and/or intra-articular glucocorticoids within 4 weeks prior to baseline\n* Use of oral glucocorticoids greater than 10 mg/day prednisone (or equivalent), or change in dosage within 2 weeks prior to baseline\n* Prior documented history of no response to hydroxychloroquine and sulfasalazine\n* Prior use of cDMARDs (other than MTX) within the following windows prior to baseline (cDMARDs were not to be discontinued to facilitate a subject's participation in the study, but should instead have been previously discontinued as part of a subject's medical management of RA):\n\n  1. 4 weeks for sulfasalazine, azathioprine, cyclosporine, hydroxychloroquine, chloroquine, gold, penicillamine, minocycline, or doxycycline\n  2. 12 weeks for leflunomide unless the subject has completed the following elimination procedure at least 4 weeks prior to baseline: Cholestyramine at a dosage of 8 grams 3 times daily for at least 24 hours, or activated charcoal at a dosage of 50 grams 4 times daily for at least 24 hours\n  3. 24 weeks for cyclophosphamide\n* Vaccination with live vaccines in the 6 weeks prior to baseline or planned vaccination with live vaccines during the study\n* Participation in any other investigational drug study within 30 days or 5 times the terminal half-life of the investigational drug, whichever is longer, prior to baseline\n* Other treatments for RA (e.g., Prosorba Device/Column) within 6 months prior to baseline\n* Use of intra-articular hyaluronic acid injections within 4 weeks prior to baseline\n* Use of non-steroidal anti-inflammatory drugs (NSAIDs) on unstable dose or switching of NSAIDs within 2 weeks prior to baseline\n* Previous participation in this study (randomized) or another study of OKZ\n* Subjects with acute or chronic viral hepatitis B or C infection as detected by blood tests at Screening (e.g., positive for hepatitis B surface antigen \\[HBsAg\\], total hepatitis B core antibody \\[anti-HBc\\], or hepatitis C virus antibody \\[HCV Ab\\])\n\n  a. Subjects who were positive for hepatitis B surface antibody (anti-HBs), but negative for HBsAg and anti-HBc, were eligible\n* Subjects with HIV infection\n* Subjects with:\n\n  1. Suspected or confirmed current active TB disease or a history of active TB disease\n  2. Close contact (i.e., sharing the same household or other enclosed environment, such as a social gathering place, workplace, or facility, for extended periods during the day) with an individual with active TB within 1.5 years prior to Screening.\n* Concurrent malignancy or a history of malignancy within the last 5 years (with the exception of successfully treated carcinoma in situ of the cervix and successfully treated basal cell carcinoma and squamous cell carcinoma not less than 1 year prior to Screening \\[and no more than 3 excised skin cancers within the last 5 years prior to Screening\\])\n* Subjects with any infection requiring oral antibiotic or antiviral therapy in the 2 weeks prior to Screening or at baseline, injectable anti-infective therapy in the last 4 weeks prior to baseline, or serious or recurrent infection with a history of hospitalization in the 6 months prior to baseline\n* Subjects with evidence of disseminated herpes zoster infection, zoster encephalitis, meningitis, or other non-self-limited herpes zoster infections in the 6 months prior to baseline\n* Subjects with planned surgery during the study or surgery ≤4 weeks prior to Screening and from which the subject had not fully recovered, as judged by the Investigator\n* Subjects with diverticulitis or other symptomatic GI conditions that might predispose the subject to perforations, including subjects with a history of such predisposing conditions (e.g., diverticulitis, GI perforation, or ulcerative colitis)\n* Pre-existing central nervous system demyelinating disorders (e.g., multiple sclerosis and optic neuritis)\n* History of chronic alcohol or drug abuse as judged by the Investigator\n* Female subjects who are pregnant, currently lactating, have lactated within the last 12 weeks, or who were planning to become pregnant during the study or within 6 months of last dose of study treatment\n* Female subjects of childbearing potential (unless permanent cessation of menstrual periods, determined retrospectively after a woman had experienced 12 months of natural amenorrhea as defined by the amenorrhea with underlying status \\[e.g., correlative age\\] or 6 months of natural amenorrhea with documented serum follicle-stimulating hormone levels \\>40 mIU/mL and estradiol \\<20 pg/mL) who were not willing to use a highly effective method of contraception during the study and for at least 6 months after the last administration of study treatment OR Male subjects with partners of childbearing potential not willing to use a highly effective method of contraception during the study and for at least 3 months after the last administration of study treatment;\n* Subjects with a known hypersensitivity to any component of the OKZ drug product, or placebo\n* Subjects with a known hypersensitivity or contraindication to any component of the rescue medication\n* History of severe allergic or anaphylactic reactions to human, humanized, or murine monoclonal antibodies\n\nThe above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Subjects Achieving American College of Rheumatology 20% (ACR20) Response","description":"A responder was defined as any subject satisfying ACR20 criteria and remaining on randomized treatment and in the study at Week 12.\n\nThe calculations were based on a ≥ 20% improvement from baseline in the swollen joint count (SJC) assessed in 66 joints and in the tender joint count (TJC) assessed in 68 joints; and a ≥ 20% improvement from baseline in at least 3 of the 5 remaining core set measures: Patient Global Assessment of Disease Activity (Visual Analog Scale (VAS) assessment), Patient Assessment of Pain (VAS assessment), Health Assessment Questionnaire-Disability Index (HAQ-DI), Physician Global Assessment (VAS assessment), Level of acute phase reactant (CRP or ESR, using level of CRP in this study).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"91","spread":null},{"groupId":"OG002","value":"37","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects Achieving Low Disease Activity","description":"Defined as Disease Activity Score 28 (DAS28) (CRP) \\< 3.2, and remaining on randomized treatment and in the study at Week 12.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"55","spread":null},{"groupId":"OG001","value":"47","spread":null},{"groupId":"OG002","value":"5","spread":null}]}]}]},{"type":"SECONDARY","title":"Improvement of Physical Ability From Baseline to Week 12, as Measured by the Health Assessment Questionnaire Disability Index (HAQ-DI)","description":"Change of physical ability from baseline (the last available assessment prior to the first dose of the study treatment) to week 12, as measured by HAQ-DI. The HAQ-DI total score ranges from 0 (the best outcome) to 3 (the worst outcome).The HAQ-DI assesses the degree of difficulty experienced in 8 domains (dressing and grooming, arising, eating, walking, hygiene, reach, grip, common daily activities) of daily living activities using 20 questions. Each domain consists of 2 or 3 items. For each question the level of difficulty is scored from 0 (without any difficulty, the best outcome) to 3 (unable to do, the worst outcome). Each category is given a score by taking the maximum score of each question. The HAQ-DI was calculated by dividing the sum of the category scores by the number of categories with at least 1 question answered. If fewer than 6 categories had responses, no disability score was calculated.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.52","spread":"0.046"},{"groupId":"OG001","value":"-0.55","spread":"0.047"},{"groupId":"OG002","value":"-0.23","spread":"0.044"}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects Achieving American College of Rheumatology 50% (ACR50) Response","description":"A responder was defined as any subject satisfying ACR50 criteria and remaining on randomized treatment and in the study at Week 24.\n\nThe calculations were based on a ≥ 50% improvement from baseline in the swollen joint count (SJC) assessed in 66 joints and in the tender joint count (TJC) assessed in 68 joints; and a ≥ 50% improvement from baseline in at least 3 of the 5 remaining core set measures: Patient Global Assessment of Disease Activity (Visual Analog Scale (VAS) assessment), Patient Assessment of Pain (VAS assessment), Health Assessment Questionnaire-Disability Index (HAQ-DI), Physician Global Assessment (VAS assessment), Level of acute phase reactant (CRP or ESR, using level of CRP in this study).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"69","spread":null},{"groupId":"OG001","value":"61","spread":null},{"groupId":"OG002","value":"11","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects With Clinical Disease Activity Index (CDAI) ≤ 2.8 (Remission)","description":"Percentage of subjects with Clinical Disease Activity Index (CDAI) ≤ 2.8 (remission) and remaining on randomized treatment and in the study at Week 24","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"12","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":8,"n":142},"commonTop":["Alanine aminotransferase increased","Aspartate aminotransferase increased","Leukopenia","White blood cell count decreased","Neutrophil count decreased"]}}}